| Field | Row 1 |
|---|---|
| adsh | 0000950170-25-064436 |
| cik | 1845337 |
| name | DAY ONE BIOPHARMACEUTICALS, INC. |
| sic | 2834 |
| countryba | US |
| stprba | CA |
| cityba | BRISBANE |
| zipba | 94005 |
| bas1 | 2000 SIERRA POINT PARKWAY, SUITE 501 |
| bas2 | |
| baph | 650 484-0899 |
| countryma | US |
| stprma | CA |
| cityma | BRISBANE |
| zipma | 94005 |
| mas1 | 2000 SIERRA POINT PARKWAY, SUITE 501 |
| mas2 | |
| countryinc | US |
| stprinc | DE |
| ein | 832415215 |
| former | DAY ONE BIOPHARMACEUTICALS HOLDING CO LLC |
| changed | 20210209 |
| afs | 1-LAF |
| wksi | 0 |
| fye | 1231 |
| form | 10-Q |
| period | 20250331 |
| fy | 2025 |
| fp | Q1 |
| filed | 20250506 |
| accepted | 2025-05-06 16:06:00.0 |
| prevrpt | 0 |
| detail | 1 |
| instance | dawn-20250331_htm.xml |
| nciks | 1 |
| aciks |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| cik | Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings. |
| name | Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date. |
| sic | Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business. |
| countryba | The ISO 3166-1 country of the registrant's business address. |
| stprba | The state or province of the registrant’s business address, if field countryba is US or CA. |
| cityba | The city of the registrant's business address. |
| zipba | The zip code of the registrant’s business address. |
| bas1 | The first line of the street of the registrant’s business address. |
| bas2 | The second line of the street of the registrant’s business address. |
| baph | The phone number of the registrant’s business address. |
| countryma | The ISO 3166-1 country of the registrant's mailing address. |
| stprma | The state or province of the registrant’s mailing address, if field countryma is US or CA. |
| cityma | The city of the registrant's mailing address. |
| zipma | The zip code of the registrant’s mailing address. |
| mas1 | The first line of the street of the registrant’s mailing address. |
| mas2 | The second line of the street of the registrant’s mailing address. |
| countryinc | The ISO 3166-1 country of incorporation for the registrant. |
| stprinc | The state or province of incorporation for the registrant, if countryinc is US or CA. |
| ein | Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States. |
| former | Most recent former name of the registrant, if any. |
| changed | Date of change from the former name, if any. |
| afs | Filer status with the SEC at the time of submission: 1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned. |
| wksi | Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement. |
| fye | Fiscal Year End Date, rounded to nearest month-end. |
| form | The submission type of the registrant’s filing. |
| period | Balance Sheet Date, rounded to nearest month-end. |
| fy | Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8). |
| fp | Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year. |
| filed | The date of the registrant’s filing with the Commission. |
| accepted | The acceptance date and time of the registrant’s filing with the Commission. |
| prevrpt | Previous Report – TRUE indicates that the submission information was subsequently amended. |
| detail | TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount). |
| instance | The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol. |
| nciks | Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing. |
| aciks | Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information. |
| adsh | ddate | tag | value | uom | qtrs | version | segments | coreg | footnote |
|---|---|---|---|---|---|---|---|---|---|
| 0000950170-25-064436 | 20241231 | Assets | 582788000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Accretion Amortization Of Discounts And Premiums Investments | 4250000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20241231 | Additional Paid In Capital | 1056738000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Additional Paid In Capital | 1069631000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Allocated Share Based Compensation Expense | 4653000.0000 | USD | 1 | us-gaap/2024 | Income Statement Location= Research And Development Expense; | ||
| 0000950170-25-064436 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -91610000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0000950170-25-064436 | 20250331 | Earnings Per Share Basic | -0.3500 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Net Cash Provided By Used In Financing Activities | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Net Income Loss | -62412000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Operating Lease Right Of Use Asset | 2577000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Operating Lease Right Of Use Asset Amortization Expense | 75000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax | -136000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-064436 | 20240331 | Payments To Acquire Intangible Assets | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Payments To Acquire Property Plant And Equipment | 317000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Proceeds From Sale Of Short Term Investments | 161000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Property Plant And Equipment Net | 2508000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Right Of Use Asset Obtained In Exchange For Operating Lease Liability | 230000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20231231 | Shares Outstanding | 87227132.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Shares; | ||
| 0000950170-25-064436 | 20241231 | Shares Outstanding | 101116162.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Shares; | ||
| 0000950170-25-064436 | 20231231 | Stockholders Equity | 9000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-064436 | 20231231 | Stockholders Equity | 9000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Shares; | ||
| 0000950170-25-064436 | 20231231 | Stockholders Equity | -458585000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-064436 | 20240331 | Stockholders Equity | 9000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Shares; | ||
| 0000950170-25-064436 | 20240331 | Stock Issued During Period Value Stock Options Exercised | 100000.0000 | USD | 1 | us-gaap/2024 | Plan Name= Two Thousand And Twenty One Equity Incentive Plan; | ||
| 0000950170-25-064436 | 20240331 | Weighted Average Number Of Diluted Shares Outstanding | 86679282.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Income Loss Attributable To Noncontrolling Interest | 62412000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Accounts Payable Current | 2540000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Accumulated Other Comprehensive Income Loss Net Of Tax | -52000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Assets | 534356000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20241231 | Cash And Cash Equivalents At Carrying Value | 16728000.0000 | USD | 0 | us-gaap/2024 | Financial Instrument= Money Market Funds; | ||
| 0000950170-25-064436 | 20250331 | Cash And Cash Equivalents At Carrying Value | 12146000.0000 | USD | 0 | us-gaap/2024 | Financial Instrument= Money Market Funds; | ||
| 0000950170-25-064436 | 20240331 | Comprehensive Income Net Of Tax | -62426000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20241231 | Deferred Revenue Current | 1554000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Deferred Revenue Noncurrent | 3350000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Income Tax Expense Benefit | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Increase Decrease In Accrued Expenses And Other Current Liabilities | -1765000.0000 | USD | 1 | 0000950170-25-064436 | |||
| 0000950170-25-064436 | 20250331 | Increase Decrease In Inventories And Other Operating Assets | 212000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Increase Decrease In Operating Lease Liability | -108000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Inventory Net | 3565000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Net Cash Provided By Used In Investing Activities | -32613000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Operating Income Loss | -66767000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20241231 | Operating Lease Liability Noncurrent | 2592000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Operating Lease Liability Noncurrent | 2854000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20241231 | Receivables Net Current | 13876000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Right Of Use Asset Obtained In Exchange For Operating Lease Liability | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Stockholders Equity | 817799000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-064436 | 20240331 | Stockholders Equity | -520997000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-064436 | 20241231 | Stockholders Equity | 84000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-064436 | 20250331 | Stockholders Equity | -590077000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-064436 | 20250331 | Accrued Liabilities And Other Liabilities | 43641000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 12644000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Amortization Of Intangible Assets | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20241231 | Cash And Cash Equivalents At Carrying Value | 124968000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 270391000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 124968000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Common Stock Par Or Stated Value Per Share | 0.0001 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20241231 | Common Stock Shares Issued | 101116162.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Common Stock Shares Issued | 101353781.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Common Stock Value | 10000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Cost Of Product Revenue | 0.0000 | USD | 1 | 0000950170-25-064436 | |||
| 0000950170-25-064436 | 20250331 | Deferred Revenue Current | 1600000.0000 | USD | 0 | us-gaap/2024 | Fair Value By Asset Class= Current; Type Of Arrangement= License Agreement With Ipsen Pharma Sas; | ||
| 0000950170-25-064436 | 20250331 | Earnings Per Share Diluted | -0.3500 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Increase Decrease In Accrued Expenses And Other Current Liabilities | -26984000.0000 | USD | 1 | 0000950170-25-064436 | |||
| 0000950170-25-064436 | 20250331 | Increase Decrease In Deferred Revenue | 199000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Investment Income Net | 4365000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Investment Income Net | 5094000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Issuance Of Common Stock Upon Release Of Restricted Stock Units | 157724.0000 | shares | 1 | 0000950170-25-064436 | Equity Components= Common Shares; | ||
| 0000950170-25-064436 | 20241231 | Liabilities And Stockholders Equity | 582788000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Liabilities And Stockholders Equity | 534356000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Net Income Loss | -35996000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-064436 | 20250331 | Nonoperating Income Expense | 5071000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20241231 | Operating Lease Liability Current | 10000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Operating Lease Right Of Use Asset Amortization Expense | 93000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Operating Lease Right Of Use Asset Amortization Expense | 100000.0000 | USD | 1 | us-gaap/2024 | Lease Contractual Term= Lease For Corporate Office Facility; | ||
| 0000950170-25-064436 | 20250331 | Operating Lease Right Of Use Asset Amortization Expense | 100000.0000 | USD | 1 | us-gaap/2024 | Lease Contractual Term= Lease For Corporate Office Facility; | ||
| 0000950170-25-064436 | 20241231 | Other Liabilities Noncurrent | 761000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Prepaid Expense And Other Assets Current | 14012000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Revenues | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Stockholders Equity | 296806000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Stock Issued During Period Shares Share Based Compensation Forfeited | -12555.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Shares; | ||
| 0000950170-25-064436 | 20240331 | Stock Issued During Period Shares Stock Options Exercised | 4862.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Shares; | ||
| 0000950170-25-064436 | 20240331 | Weighted Average Number Of Shares Outstanding Basic | 86679282.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Weighted Average Number Of Shares Outstanding Basic | 102710382.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Amortization Of Intangible Assets | 725000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20241231 | Assets Current | 562330000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 12893000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-064436 | 20241231 | Cash And Cash Equivalents At Carrying Value | 104838000.0000 | USD | 0 | us-gaap/2024 | Financial Instrument= Cash Equivalents; | ||
| 0000950170-25-064436 | 20240331 | Accretion Amortization Of Discounts And Premiums Investments | 1292000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 12893000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Allocated Share Based Compensation Expense | 200000.0000 | USD | 1 | us-gaap/2024 | Plan Name= Two Thousand And Twenty One Employee Stock Purchase Plan; | ||
| 0000950170-25-064436 | 20241231 | Common Stock Par Or Stated Value Per Share | 0.0001 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Common Stock Shares Authorized | 500000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Common Stock Shares Authorized | 500000000.0000 | shares | 0 | us-gaap/2024 | Agreement= Common Shares Purchase Agreement; | ||
| 0000950170-25-064436 | 20250331 | Common Stock Shares Outstanding | 101353781.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Deferred Revenue Noncurrent | 3400000.0000 | USD | 0 | us-gaap/2024 | Fair Value By Asset Class= Noncurrent; Type Of Arrangement= License Agreement With Ipsen Pharma Sas; | ||
| 0000950170-25-064436 | 20240331 | General And Administrative Expense | 26557000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | General And Administrative Expense | 29325000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Increase Decrease In Deferred Revenue | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Increase Decrease In Deposit Other Assets | -47000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | 606000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Net Cash Provided By Used In Operating Activities | -58997000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Other Liabilities Noncurrent | 761000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Other Nonoperating Income Expense | -10000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Revenues | 0.0000 | USD | 1 | us-gaap/2024 | Product Or Service= License; | ||
| 0000950170-25-064436 | 20241231 | Accrued Liabilities And Other Liabilities | 68625000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Allocated Share Based Compensation Expense | 12861000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Allocated Share Based Compensation Expense | 8610000.0000 | USD | 1 | us-gaap/2024 | Income Statement Location= Selling General And Administrative Expenses; | ||
| 0000950170-25-064436 | 20241231 | Cash And Cash Equivalents At Carrying Value | 75163000.0000 | USD | 0 | us-gaap/2024 | Financial Instrument= U S Government Corporations And Agencies Securities; | ||
| 0000950170-25-064436 | 20250331 | Cash And Cash Equivalents At Carrying Value | 33358000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Cash And Cash Equivalents At Carrying Value | 12146000.0000 | USD | 0 | us-gaap/2024 | Financial Instrument= Cash Equivalents; | ||
| 0000950170-25-064436 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | 39607000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20241231 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0000950170-25-064436 | 20250331 | Common Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | Ownership= At The Market; | ||
| 0000950170-25-064436 | 20250331 | Comprehensive Income Net Of Tax | -36132000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Cost Of Product Revenue | 2884000.0000 | USD | 1 | 0000950170-25-064436 | |||
| 0000950170-25-064436 | 20250331 | Increase Decrease In Operating Lease Liability | 91000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Net Cash Provided By Used In Investing Activities | 89288000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Net Cash Provided By Used In Operating Activities | -49729000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Operating Expenses | 66767000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Operating Expenses | 71828000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax | -14000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-064436 | 20250331 | Other Nonoperating Income Expense | -23000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Payments To Acquire Property Plant And Equipment | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20241231 | Prepaid Expense And Other Assets Current | 13413000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Proceeds From Sale Of Short Term Investments | 136450000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Shares Outstanding | 101353781.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Shares; | ||
| 0000950170-25-064436 | 20241231 | Short Term Investments | 406752000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20241231 | Stockholders Equity | 502751000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Stockholders Equity | 479512000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Payments To Acquire Short Term Investments | 47162000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Proceeds From Stock Options Exercised | 48000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Revenues | 30761000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Shares Outstanding | 87377163.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Shares; | ||
| 0000950170-25-064436 | 20240331 | Stockholders Equity | -5000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-064436 | 20241231 | Stockholders Equity | 1056738000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-064436 | 20241231 | Stockholders Equity | -554081000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-064436 | 20250331 | Stockholders Equity | -52000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-064436 | 20240331 | Stock Issued During Period Value Stock Options Exercised | 48000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-064436 | 20241231 | Accounts Payable Current | 3262000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20241231 | Accumulated Other Comprehensive Income Loss Net Of Tax | 84000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 12644000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-064436 | 20240331 | Allocated Share Based Compensation Expense | 12644000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Assets Current | 508651000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Capital Expenditures Incurred But Not Yet Paid | 2000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20241231 | Cash And Cash Equivalents At Carrying Value | 12947000.0000 | USD | 0 | us-gaap/2024 | Financial Instrument= U S Treasury Securities; | ||
| 0000950170-25-064436 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 33358000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240731 | Common Stock Par Or Stated Value Per Share | 0.0001 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-064436 | 20240731 | Common Stock Value | 40000000.0000 | USD | 0 | us-gaap/2024 | Agreement= Investment Agreement; Equity Components= Common Stock; | ||
| 0000950170-25-064436 | 20240331 | Earnings Per Share Diluted | -0.7200 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Income Tax Expense Benefit | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | -837000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20241231 | Indefinite Lived Intangible Assets Excluding Goodwill | 15630000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Net Cash Provided By Used In Financing Activities | 48000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Operating Lease Liability Current | 62000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20241231 | Operating Lease Right Of Use Asset | 2422000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Proceeds From Stock Options Exercised | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Receivables Net Current | 18054000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Research And Development Expense | 39619000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Retained Earnings Accumulated Deficit | -590077000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20231231 | Stockholders Equity | 805107000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-064436 | 20250331 | Stock Issued During Period Shares Share Based Compensation Forfeited | -735.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Shares; | ||
| 0000950170-25-064436 | 20240331 | Stock Issued During Period Value Stock Options Exercised | 48000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Capital Expenditures Incurred But Not Yet Paid | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 230784000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Common Stock Par Or Stated Value Per Share | 0.0001 | USD | 0 | us-gaap/2024 | Agreement= Common Shares Purchase Agreement; | ||
| 0000950170-25-064436 | 20241231 | Common Stock Shares Authorized | 500000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Deferred Revenue Current | 1636000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20241231 | Deposits And Other Longterm Assets Non Current | 121000.0000 | USD | 0 | 0000950170-25-064436 | |||
| 0000950170-25-064436 | 20240331 | Depreciation Depletion And Amortization | 23000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Depreciation Depletion And Amortization | 94000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Earnings Per Share Basic | -0.7200 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Increase Decrease In Accounts Payable | 2204000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Increase Decrease In Accounts Payable | -722000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Increase Decrease In Accounts Receivable | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Increase Decrease In Accounts Receivable | 4178000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Increase Decrease In Deposit Other Assets | 94000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Increase Decrease In Inventories And Other Operating Assets | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Indefinite Lived Intangible Assets Excluding Goodwill | 20405000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20241231 | Inventory Net | 3321000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Liabilities | 54844000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20241231 | Liabilities Current | 73451000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Liabilities Current | 47879000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Net Income Loss | -35996000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Nonoperating Income Expense | 4355000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Operating Income Loss | -41067000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax | -14000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax | -136000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Payments To Acquire Intangible Assets | 3500000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20241231 | Property Plant And Equipment Net | 2285000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Revenues | 30503000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Product; | ||
| 0000950170-25-064436 | 20250331 | Short Term Investments | 439662000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20241231 | Stockholders Equity | 10000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Shares; | ||
| 0000950170-25-064436 | 20250331 | Stockholders Equity | 1069631000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-064436 | 20250331 | Stock Issued During Period Value Stock Options Exercised | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Allocated Share Based Compensation Expense | 7991000.0000 | USD | 1 | us-gaap/2024 | Income Statement Location= Selling General And Administrative Expenses; | ||
| 0000950170-25-064436 | 20240331 | Allocated Share Based Compensation Expense | 200000.0000 | USD | 1 | us-gaap/2024 | Plan Name= Two Thousand And Twenty One Employee Stock Purchase Plan; | ||
| 0000950170-25-064436 | 20250331 | Allocated Share Based Compensation Expense | 4251000.0000 | USD | 1 | us-gaap/2024 | Income Statement Location= Research And Development Expense; | ||
| 0000950170-25-064436 | 20240731 | Common Stock Shares Issued | 10551718.0000 | shares | 0 | us-gaap/2024 | Agreement= Two Thousand Twenty Four Private Placement; | ||
| 0000950170-25-064436 | 20241231 | Common Stock Shares Outstanding | 101116162.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240731 | Common Stock Value | 32600000.0000 | USD | 0 | us-gaap/2024 | Agreement= Investment Agreement; | ||
| 0000950170-25-064436 | 20241231 | Common Stock Value | 10000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20241231 | Deferred Revenue Noncurrent | 3233000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Deposits And Other Longterm Assets Non Current | 215000.0000 | USD | 0 | 0000950170-25-064436 | |||
| 0000950170-25-064436 | 20250331 | Income Loss Attributable To Noncontrolling Interest | 35996000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Issuance Of Common Stock Upon Release Of Restricted Stock Units | 238354.0000 | shares | 1 | 0000950170-25-064436 | Equity Components= Common Shares; | ||
| 0000950170-25-064436 | 20241231 | Liabilities | 80037000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Net Income Loss | -62412000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-064436 | 20250331 | Payments To Acquire Short Term Investments | 189796000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Research And Development Expense | 40210000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20241231 | Retained Earnings Accumulated Deficit | -554081000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20240331 | Revenues | 0.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Product; | ||
| 0000950170-25-064436 | 20250331 | Revenues | 258000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= License; | ||
| 0000950170-25-064436 | 20231231 | Stockholders Equity | 346540000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064436 | 20250331 | Stockholders Equity | 10000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Shares; | ||
| 0000950170-25-064436 | 20250331 | Stock Issued During Period Shares Stock Options Exercised | 0.0000 | shares | 1 | us-gaap/2024 | Plan Name= Two Thousand And Twenty One Equity Incentive Plan; | ||
| 0000950170-25-064436 | 20250331 | Weighted Average Number Of Diluted Shares Outstanding | 102710382.0000 | shares | 1 | us-gaap/2024 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| ddate | The end date for the data value, rounded to the nearest month end. |
| qtrs | The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value. |
| uom | The unit of measure for the value. |
| segments | Tags used to represent axis and member reporting. |
| coreg | If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity. |
| value | The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point. |
| footnote | The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank. |
| tag | version | custom | abstract | datatype | iord | crdr | tlabel | doc |
|---|---|---|---|---|---|---|---|---|
| Increase Decrease In Accounts Receivable | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Accounts Receivable | The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. |
| Stock Issued During Period Value Stock Options Exercised | us-gaap/2024 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, Stock Options Exercised | Value of stock issued as a result of the exercise of stock options. |
| Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets, Current | Amount of asset recognized for present right to economic benefit, classified as current. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents | Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Increase Decrease In Deposit Other Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Deposit Assets | The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits. |
| Operating Lease Liability Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Current | Present value of lessee's discounted obligation for lease payments from operating lease, classified as current. |
| Payments To Acquire Property Plant And Equipment | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Property, Plant, and Equipment | The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. |
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | us-gaap/2024 | 0 | 0 | monetary | D | D | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | Amount of increase in right-of-use asset obtained in exchange for operating lease liability. |
| Additional Paid In Capital | us-gaap/2024 | 0 | 0 | monetary | I | C | Additional Paid in Capital | Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. |
| Comprehensive Income Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. |
| Deferred Revenue Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Deferred Revenue, Current | Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. |
| Liabilities | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities | Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. |
| Liabilities And Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
| Proceeds From Stock Options Exercised | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Stock Options Exercised | Amount of cash inflow from exercise of option under share-based payment arrangement. |
| Retained Earnings Accumulated Deficit | us-gaap/2024 | 0 | 0 | monetary | I | C | Retained Earnings (Accumulated Deficit) | Amount of accumulated undistributed earnings (deficit). |
| Short Term Investments | us-gaap/2024 | 0 | 0 | monetary | I | D | Short-Term Investments | Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. |
| Common Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Common Stock, Par or Stated Value Per Share | Face amount or stated value per share of common stock. | |
| Common Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Outstanding | Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. | |
| Income Tax Expense Benefit | us-gaap/2024 | 0 | 0 | monetary | D | D | Income Tax Expense (Benefit) | Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. |
| Net Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss) Attributable to Parent | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. |
| Receivables Net Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Receivables, Net, Current | The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value. |
| Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Attributable to Parent | Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. |
| Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Diluted | The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. | |
| Accrued Liabilities And Other Liabilities | us-gaap/2024 | 0 | 0 | monetary | I | C | Accrued Liabilities and Other Liabilities | Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. |
| Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | I | C | Accumulated Other Comprehensive Income (Loss), Net of Tax | Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. |
| Allocated Share Based Compensation Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Share-Based Payment Arrangement, Expense | Amount of expense for award under share-based payment arrangement. Excludes amount capitalized. |
| Assets | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets | Amount of asset recognized for present right to economic benefit. |
| Common Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Issued | Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. | |
| Earnings Per Share Diluted | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | |
| Operating Lease Right Of Use Asset | us-gaap/2024 | 0 | 0 | monetary | I | D | Operating Lease, Right-of-Use Asset | Amount of lessee's right to use underlying asset under operating lease. |
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax | Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. |
| Payments To Acquire Intangible Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Intangible Assets | The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. |
| Stock Issued During Period Shares Share Based Compensation Forfeited | us-gaap/2024 | 0 | 0 | shares | D | Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited | Number of shares (or other type of equity) forfeited during the period. | |
| Depreciation Depletion And Amortization | us-gaap/2024 | 0 | 0 | monetary | D | D | Depreciation, Depletion and Amortization | The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. |
| Cost Of Product Revenue | 0000950170-25-064436 | 1 | 0 | monetary | D | D | cost of product revenue | Cost of Product Revenue |
| Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. |
| Deposits And Other Longterm Assets Non Current | 0000950170-25-064436 | 1 | 0 | monetary | I | D | Deposits and other longterm assets Non current | Deposits and other long-term assets Non current. |
| Issuance Of Common Stock Upon Release Of Restricted Stock Units | 0000950170-25-064436 | 1 | 0 | shares | D | Issuance of common stock upon release of restricted stock units | Issuance of common stock upon release of restricted stock units | |
| Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash and Cash Equivalents, at Carrying Value | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. |
| Deferred Revenue Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Deferred Revenue, Noncurrent | Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent. |
| Increase Decrease In Inventories And Other Operating Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Inventories and Other Operating Assets | Amount of increase (decrease) in inventory, and assets classified as other. |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Prepaid Expense and Other Assets | Amount of increase (decrease) in prepaid expenses, and assets classified as other. |
| Nonoperating Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Nonoperating Income (Expense) | The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). |
| Proceeds From Sale Of Short Term Investments | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Sale of Short-Term Investments | The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. |
| Capital Expenditures Incurred But Not Yet Paid | us-gaap/2024 | 0 | 0 | monetary | D | C | Capital Expenditures Incurred but Not yet Paid | Future cash outflow to pay for purchases of fixed assets that have occurred. |
| Net Cash Provided By Used In Operating Activities | us-gaap/2024 | 0 | 0 | monetary | D | Net Cash Provided by (Used in) Operating Activities | Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. | |
| Operating Expenses | us-gaap/2024 | 0 | 0 | monetary | D | D | Operating Expenses | Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. |
| Operating Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Operating Income (Loss) | The net result for the period of deducting operating expenses from operating revenues. |
| Other Liabilities Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Other Liabilities, Noncurrent | Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer. |
| Prepaid Expense And Other Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Prepaid Expense and Other Assets, Current | Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | us-gaap/2024 | 0 | 0 | monetary | D | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect | Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Common Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Common Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| General And Administrative Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | General and Administrative Expense | The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. |
| Inventory Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Inventory, Net | Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. |
| Research And Development Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Research and Development Expense | Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. |
| Revenues | us-gaap/2024 | 0 | 0 | monetary | D | C | Revenues | Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). |
| Accounts Payable Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accounts Payable, Current | Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Amortization Of Intangible Assets | us-gaap/2024 | 0 | 0 | monetary | D | D | Amortization of Intangible Assets | The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. |
| Commitments And Contingencies | us-gaap/2024 | 0 | 0 | monetary | I | C | Commitments and Contingencies | Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. |
| Common Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares Authorized | The maximum number of common shares permitted to be issued by an entity's charter and bylaws. | |
| Income Loss Attributable To Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | D | D | Income (Loss) Attributable to Noncontrolling Interest, before Tax | Amount, before tax, of income (loss) attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments. |
| Increase Decrease In Accounts Payable | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accounts Payable | The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. |
| Increase Decrease In Operating Lease Liability | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Operating Lease Liability | Amount of increase (decrease) in obligation for operating lease. |
| Indefinite Lived Intangible Assets Excluding Goodwill | us-gaap/2024 | 0 | 0 | monetary | I | D | Indefinite-Lived Intangible Assets (Excluding Goodwill) | Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit. |
| Investment Income Net | us-gaap/2024 | 0 | 0 | monetary | D | C | Investment Income, Net | Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities. |
| Net Cash Provided By Used In Financing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Financing Activities | Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. |
| Operating Lease Right Of Use Asset Amortization Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Operating Lease, Right-of-Use Asset, Periodic Reduction | Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. |
| Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Shares, Outstanding | Number of shares issued which are neither cancelled nor held in the treasury. | |
| Accretion Amortization Of Discounts And Premiums Investments | us-gaap/2024 | 0 | 0 | monetary | D | C | Accretion (Amortization) of Discounts and Premiums, Investments | The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | 0 | 0 | monetary | D | C | APIC, Share-Based Payment Arrangement, Increase for Cost Recognition | Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. |
| Earnings Per Share Basic | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | |
| Net Cash Provided By Used In Investing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Investing Activities | Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. |
| Other Nonoperating Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Nonoperating Income (Expense) | Amount of income (expense) related to nonoperating activities, classified as other. |
| Stock Issued During Period Shares Stock Options Exercised | us-gaap/2024 | 0 | 0 | shares | D | Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period | Number of share options (or share units) exercised during the current period. | |
| Increase Decrease In Deferred Revenue | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Deferred Revenue | Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. |
| Operating Lease Liability Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Noncurrent | Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. |
| Payments To Acquire Short Term Investments | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Short-Term Investments | The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. |
| Property Plant And Equipment Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Property, Plant and Equipment, Net | Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. |
| Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Basic | Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. | |
| Increase Decrease In Accrued Expenses And Other Current Liabilities | 0000950170-25-064436 | 1 | 0 | monetary | D | D | Increase (Decrease) In Accrued Expenses And Other Current Liabilities | Increase (decrease) in accrued expenses and other current liabilities. |
| Field Name | Field Description |
|---|---|
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| custom | 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns. |
| abstract | 1 if the tag is not used to represent a numeric fact. |
| datatype | If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag. |
| iord | If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration. |
| crdr | If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL. |
| tlabel | If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here. |
| doc | The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL. |
| adsh | report | line | stmt | inpth | rfile | tag | version | plabel | negating |
|---|---|---|---|---|---|---|---|---|---|
| 0000950170-25-064436 | 2 | 3 | BS | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | Cash and cash equivalents | 0 |
| 0000950170-25-064436 | 2 | 4 | BS | 0 | H | Short Term Investments | us-gaap/2024 | Short-term investments | 0 |
| 0000950170-25-064436 | 2 | 5 | BS | 0 | H | Receivables Net Current | us-gaap/2024 | Accounts receivable, net | 0 |
| 0000950170-25-064436 | 2 | 6 | BS | 0 | H | Inventory Net | us-gaap/2024 | Inventory | 0 |
| 0000950170-25-064436 | 2 | 7 | BS | 0 | H | Prepaid Expense And Other Assets Current | us-gaap/2024 | Prepaid expenses and other current assets | 0 |
| 0000950170-25-064436 | 2 | 8 | BS | 0 | H | Assets Current | us-gaap/2024 | Total current assets | 0 |
| 0000950170-25-064436 | 2 | 9 | BS | 0 | H | Property Plant And Equipment Net | us-gaap/2024 | Property and equipment, net | 0 |
| 0000950170-25-064436 | 2 | 10 | BS | 0 | H | Operating Lease Right Of Use Asset | us-gaap/2024 | Operating lease right-of-use asset | 0 |
| 0000950170-25-064436 | 2 | 11 | BS | 0 | H | Indefinite Lived Intangible Assets Excluding Goodwill | us-gaap/2024 | Intangible assets, net | 0 |
| 0000950170-25-064436 | 2 | 12 | BS | 0 | H | Deposits And Other Longterm Assets Non Current | 0000950170-25-064436 | Deposits and other long-term assets | 0 |
| 0000950170-25-064436 | 2 | 13 | BS | 0 | H | Assets | us-gaap/2024 | Total assets | 0 |
| 0000950170-25-064436 | 2 | 16 | BS | 0 | H | Accounts Payable Current | us-gaap/2024 | Accounts payable | 0 |
| 0000950170-25-064436 | 2 | 17 | BS | 0 | H | Accrued Liabilities And Other Liabilities | us-gaap/2024 | Accrued expenses and other current liabilities | 0 |
| 0000950170-25-064436 | 2 | 18 | BS | 0 | H | Deferred Revenue Current | us-gaap/2024 | Current portion of deferred revenue | 0 |
| 0000950170-25-064436 | 2 | 19 | BS | 0 | H | Operating Lease Liability Current | us-gaap/2024 | Current portion of operating lease liabilities | 0 |
| 0000950170-25-064436 | 2 | 20 | BS | 0 | H | Liabilities Current | us-gaap/2024 | Total current liabilities | 0 |
| 0000950170-25-064436 | 2 | 21 | BS | 0 | H | Deferred Revenue Noncurrent | us-gaap/2024 | Long-term portion of deferred revenue | 0 |
| 0000950170-25-064436 | 2 | 22 | BS | 0 | H | Operating Lease Liability Noncurrent | us-gaap/2024 | Long-term portion of operating lease liabilities | 0 |
| 0000950170-25-064436 | 2 | 23 | BS | 0 | H | Other Liabilities Noncurrent | us-gaap/2024 | Other long-term liability | 0 |
| 0000950170-25-064436 | 2 | 24 | BS | 0 | H | Liabilities | us-gaap/2024 | Total liabilities | 0 |
| 0000950170-25-064436 | 2 | 25 | BS | 0 | H | Commitments And Contingencies | us-gaap/2024 | Commitments and contingencies (Note 6) | 0 |
| 0000950170-25-064436 | 2 | 27 | BS | 0 | H | Common Stock Value | us-gaap/2024 | Common stock, $0.0001 par value; 500,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 101,353,781 and 101,116,162 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively. | 0 |
| 0000950170-25-064436 | 2 | 28 | BS | 0 | H | Additional Paid In Capital | us-gaap/2024 | Additional paid-in-capital | 0 |
| 0000950170-25-064436 | 2 | 29 | BS | 0 | H | Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | Accumulated other comprehensive (loss) income | 0 |
| 0000950170-25-064436 | 2 | 30 | BS | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2024 | Accumulated deficit | 0 |
| 0000950170-25-064436 | 2 | 31 | BS | 0 | H | Stockholders Equity | us-gaap/2024 | Total stockholders' equity | 0 |
| 0000950170-25-064436 | 2 | 32 | BS | 0 | H | Liabilities And Stockholders Equity | us-gaap/2024 | Total liabilities and stockholders' equity | 0 |
| 0000950170-25-064436 | 3 | 5 | BS | 1 | H | Common Stock Par Or Stated Value Per Share | us-gaap/2024 | Common Stock, Par or Stated Value Per Share | 0 |
| 0000950170-25-064436 | 3 | 6 | BS | 1 | H | Common Stock Shares Authorized | us-gaap/2024 | Common Stock, Shares Authorized | 0 |
| 0000950170-25-064436 | 3 | 7 | BS | 1 | H | Common Stock Shares Issued | us-gaap/2024 | Common Stock, Shares Issued | 0 |
| 0000950170-25-064436 | 3 | 8 | BS | 1 | H | Common Stock Shares Outstanding | us-gaap/2024 | Common Stock, Shares Outstanding | 0 |
| 0000950170-25-064436 | 4 | 8 | IS | 0 | H | Revenues | us-gaap/2024 | Total revenues | 0 |
| 0000950170-25-064436 | 4 | 10 | IS | 0 | H | Cost Of Product Revenue | 0000950170-25-064436 | Cost of product revenue | 0 |
| 0000950170-25-064436 | 4 | 11 | IS | 0 | H | Research And Development Expense | us-gaap/2024 | Research and development | 0 |
| 0000950170-25-064436 | 4 | 12 | IS | 0 | H | General And Administrative Expense | us-gaap/2024 | Selling, general and administrative | 0 |
| 0000950170-25-064436 | 4 | 13 | IS | 0 | H | Operating Expenses | us-gaap/2024 | Total cost and operating expenses | 0 |
| 0000950170-25-064436 | 4 | 14 | IS | 0 | H | Operating Income Loss | us-gaap/2024 | Loss from operations | 0 |
| 0000950170-25-064436 | 4 | 16 | IS | 0 | H | Investment Income Net | us-gaap/2024 | Investment income, net | 0 |
| 0000950170-25-064436 | 4 | 17 | IS | 0 | H | Other Nonoperating Income Expense | us-gaap/2024 | Other income (expense), net | 0 |
| 0000950170-25-064436 | 4 | 18 | IS | 0 | H | Nonoperating Income Expense | us-gaap/2024 | Total non-operating income, net | 0 |
| 0000950170-25-064436 | 4 | 19 | IS | 0 | H | Income Loss Attributable To Noncontrolling Interest | us-gaap/2024 | Loss before income taxes | 1 |
| 0000950170-25-064436 | 4 | 20 | IS | 0 | H | Income Tax Expense Benefit | us-gaap/2024 | Income tax benefit (expense) | 0 |
| 0000950170-25-064436 | 4 | 21 | IS | 0 | H | Net Income Loss | us-gaap/2024 | Net income (loss) | 0 |
| 0000950170-25-064436 | 4 | 22 | IS | 0 | H | Earnings Per Share Basic | us-gaap/2024 | Net income (loss) per share - basic | 0 |
| 0000950170-25-064436 | 4 | 23 | IS | 0 | H | Earnings Per Share Diluted | us-gaap/2024 | Net income (loss) per share - diluted | 0 |
| 0000950170-25-064436 | 4 | 24 | IS | 0 | H | Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | Weighted-average number of common shares used in net income (loss) per share - basic | 0 |
| 0000950170-25-064436 | 4 | 25 | IS | 0 | H | Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | Weighted-average number of common shares used in net income (loss) per share - diluted | 0 |
| 0000950170-25-064436 | 5 | 3 | CI | 0 | H | Net Income Loss | us-gaap/2024 | Net Income (Loss) | 0 |
| 0000950170-25-064436 | 5 | 5 | CI | 0 | H | Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax | us-gaap/2024 | Unrealized loss on available-for-sale securities | 0 |
| 0000950170-25-064436 | 5 | 6 | CI | 0 | H | Comprehensive Income Net Of Tax | us-gaap/2024 | Total comprehensive loss | 0 |
| 0000950170-25-064436 | 6 | 12 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Beginning Balance | 0 |
| 0000950170-25-064436 | 6 | 13 | EQ | 0 | H | Shares Outstanding | us-gaap/2024 | Beginning Balance (In shares) | 0 |
| 0000950170-25-064436 | 6 | 14 | EQ | 0 | H | Stock Issued During Period Shares Stock Options Exercised | us-gaap/2024 | Issuance of common stock upon exercise of stock options (share) | 0 |
| 0000950170-25-064436 | 6 | 15 | EQ | 0 | H | Stock Issued During Period Value Stock Options Exercised | us-gaap/2024 | Issuance of common stock upon exercise of stock options, Amount | 0 |
| 0000950170-25-064436 | 6 | 16 | EQ | 0 | H | Issuance Of Common Stock Upon Release Of Restricted Stock Units | 0000950170-25-064436 | Issuance of common stock upon release of restricted stock units, shares | 0 |
| 0000950170-25-064436 | 6 | 17 | EQ | 0 | H | Stock Issued During Period Shares Share Based Compensation Forfeited | us-gaap/2024 | Unvested common stock forfeiture | 0 |
| 0000950170-25-064436 | 6 | 18 | EQ | 0 | H | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | Share-based compensation expenses | 0 |
| 0000950170-25-064436 | 6 | 19 | EQ | 0 | H | Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax | us-gaap/2024 | Unrealized loss on available-for-sale securities | 0 |
| 0000950170-25-064436 | 6 | 20 | EQ | 0 | H | Net Income Loss | us-gaap/2024 | Net Income (Loss) | 0 |
| 0000950170-25-064436 | 6 | 21 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Ending Balance | 0 |
| 0000950170-25-064436 | 6 | 22 | EQ | 0 | H | Shares Outstanding | us-gaap/2024 | Ending Balance (In shares) | 0 |
| 0000950170-25-064436 | 7 | 2 | CF | 0 | H | Net Income Loss | us-gaap/2024 | Net Income (Loss) | 0 |
| 0000950170-25-064436 | 7 | 4 | CF | 0 | H | Allocated Share Based Compensation Expense | us-gaap/2024 | Share-based compensation expense | 0 |
| 0000950170-25-064436 | 7 | 5 | CF | 0 | H | Depreciation Depletion And Amortization | us-gaap/2024 | Depreciation expense | 0 |
| 0000950170-25-064436 | 7 | 6 | CF | 0 | H | Accretion Amortization Of Discounts And Premiums Investments | us-gaap/2024 | Accretion of discounts on short-term investments, net | 1 |
| 0000950170-25-064436 | 7 | 7 | CF | 0 | H | Amortization Of Intangible Assets | us-gaap/2024 | Amortization of intangible assets | 0 |
| 0000950170-25-064436 | 7 | 8 | CF | 0 | H | Operating Lease Right Of Use Asset Amortization Expense | us-gaap/2024 | Amortization of operating right-of-use asset | 0 |
| 0000950170-25-064436 | 7 | 10 | CF | 0 | H | Increase Decrease In Accounts Receivable | us-gaap/2024 | Accounts receivable, net | 1 |
| 0000950170-25-064436 | 7 | 11 | CF | 0 | H | Increase Decrease In Inventories And Other Operating Assets | us-gaap/2024 | Inventory | 1 |
| 0000950170-25-064436 | 7 | 12 | CF | 0 | H | Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | Prepaid expenses and other current assets | 1 |
| 0000950170-25-064436 | 7 | 13 | CF | 0 | H | Increase Decrease In Deposit Other Assets | us-gaap/2024 | Deposits and other long-term assets | 1 |
| 0000950170-25-064436 | 7 | 14 | CF | 0 | H | Increase Decrease In Accounts Payable | us-gaap/2024 | Accounts payable | 0 |
| 0000950170-25-064436 | 7 | 15 | CF | 0 | H | Increase Decrease In Accrued Expenses And Other Current Liabilities | 0000950170-25-064436 | Accrued expenses and other current liabilities | 0 |
| 0000950170-25-064436 | 7 | 16 | CF | 0 | H | Increase Decrease In Deferred Revenue | us-gaap/2024 | Deferred revenue | 0 |
| 0000950170-25-064436 | 7 | 17 | CF | 0 | H | Increase Decrease In Operating Lease Liability | us-gaap/2024 | Operating lease liability | 0 |
| 0000950170-25-064436 | 7 | 18 | CF | 0 | H | Net Cash Provided By Used In Operating Activities | us-gaap/2024 | Net cash used in operating activities | 0 |
| 0000950170-25-064436 | 7 | 20 | CF | 0 | H | Payments To Acquire Short Term Investments | us-gaap/2024 | Cash paid for purchase of short-term investments | 1 |
| 0000950170-25-064436 | 7 | 21 | CF | 0 | H | Proceeds From Sale Of Short Term Investments | us-gaap/2024 | Proceeds from maturity of short-term investments | 0 |
| 0000950170-25-064436 | 7 | 22 | CF | 0 | H | Payments To Acquire Intangible Assets | us-gaap/2024 | Cash paid for acquired intangible assets | 1 |
| 0000950170-25-064436 | 7 | 23 | CF | 0 | H | Payments To Acquire Property Plant And Equipment | us-gaap/2024 | Cash paid for purchase of property and equipment | 1 |
| 0000950170-25-064436 | 7 | 24 | CF | 0 | H | Net Cash Provided By Used In Investing Activities | us-gaap/2024 | Net cash (used in) provided by investing activities | 0 |
| 0000950170-25-064436 | 7 | 26 | CF | 0 | H | Proceeds From Stock Options Exercised | us-gaap/2024 | Proceeds from issuance of common stock upon stock option exercises | 0 |
| 0000950170-25-064436 | 7 | 27 | CF | 0 | H | Net Cash Provided By Used In Financing Activities | us-gaap/2024 | Cash provided by financing activities | 0 |
| 0000950170-25-064436 | 7 | 28 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | us-gaap/2024 | Net (decrease) increase in cash and cash equivalents | 0 |
| 0000950170-25-064436 | 7 | 29 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash and cash equivalents, beginning of period | 0 |
| 0000950170-25-064436 | 7 | 30 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash and cash equivalents, end of period | 0 |
| 0000950170-25-064436 | 7 | 32 | CF | 0 | H | Capital Expenditures Incurred But Not Yet Paid | us-gaap/2024 | Capital Expenditures Incurred but Not yet Paid | 0 |
| 0000950170-25-064436 | 7 | 33 | CF | 0 | H | Right Of Use Asset Obtained In Exchange For Operating Lease Liability | us-gaap/2024 | Right-of-use asset obtained in exchange for new operating lease liabilities | 0 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| report | Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site. |
| line | Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived. |
| stmt | The financial statement location to which the value of the “report” field pertains. |
| inpth | Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700. |
| rfile | The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file. |
| tag | The tag chosen by the filer for this line item. |
| version | The taxonomy identifier if the tag is a standard tag, otherwise adsh. |
| plabel | The text presented on the line item, also known as a “preferred” label. |
| negating | Flag to indicate whether the plabel is negating. |